Time to readmission cut with injectable antipsychotics for patients with schizophrenia
Fewer patients on injectables needed medications to treat extrapyramidal symptoms, study shows.
![](https://www.ausdoc.com.au/wp-content/uploads/2024/02/4x3_injection_syringe_dreamstime_m_13172053-300x225.jpg)
For those with schizophrenia or schizoaffective disorder, long-acting injectable antipsychotics show a significant reduction in 30-day readmission compared with oral antipsychotics,
US researchers found that the 30-day readmission rate was 2% for those discharged on long-acting injectable antipsychotic medications and 8% for the oral medications group.